Table 1.
In vitro activity of cefiderocol against selected clinical isolates by susceptibility phenotype in SIDERO-WT and SIDERO-CR
| Pathogen/susceptibility phenotype (no. of isolates) | MIC90 (mg/L) [% susceptiblea] | ||||||
|---|---|---|---|---|---|---|---|
| FDC | FEP | CZA | C/T | CIP | CST | MEM | |
| SIDERO-WT [23] | |||||||
| Enterobacterales | |||||||
| MEM-nonsusceptible (246) | 4 [99.6] | > 64 [8.5] | > 64 [78.5] | > 64 [7.7] | > 8 [12.6] | > 8 [69.5] | > 64 [0] |
| CZA-nonsusceptible (57) | 4 [98.2] | > 64 [3.5] | > 64 [0] | > 64 [3.5] | > 8 [17.5] | 8 [84.7] | > 64 [7.0] |
| C/T-nonsusceptible (597) | 2 [98.8] | > 64 [25.6] | 8 [90.8] | > 64 [0] | > 8 [38.4] | > 8 [83.1] | 64 [62.0] |
| FEP-nonsusceptible (1002) | 2 [99.5] | > 64 [0] | 2 [94.5] | > 64 [55.7] | > 8 [21.9] | 8 [88.0] | 16 [75.0] |
| CIP-nonsusceptible (1299) | 2 [99.7] | > 64 [39.7] | 2 [96.4] | > 64 [71.7] | > 8 [0] | 4 [89.8] | 8 [83.5] |
| CST-nonsusceptible (930) | 1 [99.8] | 16 [87.1] | 1 [99.2] | 4 [89.1] | 4 [85.8] | > 8 [0] | 0.5 [91.9] |
| Difficult-to-treat resistantb (573) [24] | 4 [98.3] | > 64 [78.2] | > 64 [2.05] | > 8 [68.2] | |||
| Pseudomonas aeruginosa | |||||||
| MEM-nonsusceptible (1416) [25] | 1 [99.9] | 64 | 64 | > 64 | > 8 | 2 | 64 |
| CZA-nonsusceptible (113) | 1 [100] | > 64 [5.3] | > 64 [0] | > 64 [21.2] | > 8 [12.4] | 1 [99.1] | > 64 [5.3] |
| C/T-nonsusceptible (111) | 1 [100] | > 64 [6.3] | > 64 [19.8] | > 64 [0] | > 8 [12.6] | 1 [99.1] | > 64 [7.2] |
| FEP-nonsusceptible (300) | 1 [99.7] | 64 [0] | 64 [64.3] | > 64 [65.3] | > 8 [33.0] | 1 [99.0] | > 64 [30.3] |
| CIP-nonsusceptible (424) | 1 [99.8] | 32 [52.6] | 64 [76.7] | > 64 [77.1] | > 8 [0] | 1 [99.1] | > 64 [41.0] |
| Difficult-to-treat resistantb (470) [24] | 1 [99.8] | > 64 [49.5] | > 64 [48.8] | 2 [98.3] | |||
| Acinetobacter species | |||||||
| MEM-nonsusceptible (2274) [25] | 2 [94.0] | > 64 | > 64 | > 64 | > 8 | > 8 | > 64 |
| FEP-nonsusceptible (602) | 2 [94.2] | > 64 [0] | > 64c | > 64c | > 8 [3.2] | > 8 [82.6] | > 64 [11.1] |
| CIP-nonsusceptible (633) | 2 [94.5] | > 64 [7.9] | > 64c | > 64c | > 8 [0] | > 8 [82.1] | > 64 [11.4] |
| CST-nonsusceptible (114) | 2 [99.1] | > 64 [7.9] | > 64c | > 64c | > 8 [0.9] | > 8 [0] | > 64 [2.6] |
| Difficult-to-treat resistantb (1794) [24] | 2 [94.5] | > 64c | > 64c | 8 [84] | |||
| MEM-nonsusceptible B. cepacia complex (80) [25] | 2 [90.0d] | > 64 | 16 | > 64 | > 8 | > 8 | 16 |
| SIDERO-CR [27] | |||||||
| Enterobacterales | |||||||
| MEM-nonsusceptible (1022) | 4 [97.0] | > 64 [2.8] | > 64 [77.0] | > 64 [1.7] | > 8 [11.5] | > 8 [77.8] | > 64 [0] |
| MEM- and C/T-nonsusceptible (1005) | 4 [91.9] | > 64 [1.8] | > 64 [76.6] | > 64 [0] | > 8 [10.4] | > 8 [78.2] | > 64 [0] |
| MEM- and CZA-nonsusceptible (235) | 4 [96.7] | > 64 [1.3] | > 64 [0] | > 64 [0] | > 8 [15.7] | > 8 [83.8] | 32 [0] |
| P. aeruginosa | |||||||
| MDR (262) | 1 [99.2] | > 64 [13.7] | > 64 [36.3] | > 64 [24.1] | > 8 [1.2] | 1 [99.6] | > 64 [3.8] |
| MDR and C/T-nonsusceptible (199) | 2 [99.0] | > 64 [6.0] | > 64 [16.6] | > 64 [0] | > 8 [0.5] | 1 [100] | > 64 [1.5] |
| MDR and CZA-nonsusceptible (167) | 2 [98.8] | > 64 [1.8] | > 64 [0] | > 64 [0.6] | > 8 [0.6] | 1 [100] | > 64 [0] |
| MDR A. baumannii (368) | 8 [89.7] | > 64 [3.3] | > 64 | > 64 | > 8 [0] | 1 [94.6] | 32 [1.9] |
C/T ceftolozane-tazobactam, CIP ciprofloxacin, CST colistin, CZA ceftazidime-avibactam, FDC cefiderocol, FEP cefepime, MDR multidrug resistant, MEM meropenem, MIC90 minimum inhibitory concentration required to inhibit 90% of isolates
aReported only where available; bNonsusceptible to FEP, CIP and MEM according to CLSI breakpoints; cMinimum inhibitory concentration breakpoints not established; dBased on EUCAST breakpoint